Top 5 Biologics Articles of 2024

1. 2024 Formulary Moves

The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).

Read here

2. PBMs Start to Embrace Biosimilars

Pharmacy benefit managers (PBMs) are slowly coming around and putting biosimilars on their formularies. IQVIA estimates that the dearth of a Humira (adalimumab) biosimilars last year cost patients and employers cumulatively $6 billion.

Read here

3. Prolia and Xgeva Biosimilar Companies Are Queuing Up

But Amgen and Sandoz are in a patent fight over the launching of Sandoz's biosimilars to the bone-building drugs.

Read here

4. Biologics that Treat Arthritis May Lower Cardiovascular Risk

A recent study has found that biologics may have an effect on arterial wall inflammation and plaque composition, which offsets the influence of joint-derived inflammation in patients with arthritis.

Read here

5. New Biosimilars Continue to be Approved But Uptake Varies by Class

A recent IQVIA report found that uptake of biosimilars on the market for at least three years varies from 8% for insulin lispro to 82% for bevacizumab.

Read here